ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

TILS Tiziana Life Sciences Plc

58.50
0.00 (0.00%)
07 Feb 2025 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Tiziana Life Sciences Plc LSE:TILS London Ordinary Share GB00BKWNZY55 ORD 3P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 58.50 45.00 60.00 - 0.00 00:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Tiziana Life Sciences Share Discussion Threads

Showing 17751 to 17772 of 17950 messages
Chat Pages: 718  717  716  715  714  713  712  711  710  709  708  707  Older
DateSubjectAuthorDiscuss
01/2/2023
20:53
I'm still holding and hoping. The medical results look promising. One issue is possible delisting from Nasdaq as the stock is still well under a dollar. Obviously done news or progress could change that quickly. If delisting from Nasdaq does happen I'm not sure what the implications would be?
jpuff
13/1/2023
09:34
Would this possibly be a timeful entry into tlsa, as one could benefit a 50%+ profit within a twelve week timescale?.DYOR
lean5gb
11/1/2023
05:49
Before foralumab treatment, EA2's non-active SPMS disability had progressed, and EDSS worsened from 3.5 in 2018 to 6.0 in 2021 despite ocrelizumab therapy that was discontinued in 2021.

In September 2022, 8 months after starting treatment with nasal foralumab, EA2 could walk 100 meters without a cane. EDSS score improved from 6.0 to 5.5. EA2's pyramidal score remained stable during this time. In December 2022, 11 months after starting treatment with intranasal foralumab, EA2 could walk 200 meters without a cane, resulting in an even greater improvement in EDSS; with EDSS falling from a score of 5.5 to 5.0. EA2's pyramidal score continued to remain stable.

david gruen
24/11/2022
06:14
“ the auditor for Tiziana Life Sciences Ltd. (the “Company”;) resigned as auditor because in its opinion the Company no longer meets their acceptable risk criteria as, in its opinion, material weaknesses in controls over financial reporting had not been sufficiently remediated.”
marcus80
22/11/2022
20:22
i think these are traded on their otc mkt.
correct me if i am wrong!
still waiting for the annual spike!

abbynat
19/11/2022
21:40
Well,the bad news is, one of the earliest signs of cognitive impairment is the inability to finish sentences.
The good news Is

lean5gb
16/11/2022
11:05
Just need some good news
michelle74
15/11/2022
17:00
Cheer up it ain’t all bad
stenick
27/10/2022
17:29
I wonder if it'll get kicked off the Nasdaq as below a dollar a share for quite a while now. Maybe that would be the prelude to him taking it private? I'm a holder so hope that doesn't happen but the current market is grim
jpuff
11/10/2022
17:19
But at a considerably lower price
jpuff
20/9/2022
14:24
That's very true
michelle74
20/9/2022
14:20
No, but it shows they are prepared to risk their capital in the same investment as ourselves.
david gruen
20/9/2022
14:15
These directors are always buying shares, but that doesn't mean they are good stock pickers.
apollocreed1
20/9/2022
13:17
Sounds like it.
david gruen
20/9/2022
13:01
Good news at last
michelle74
20/9/2022
12:12
NEW YORK, Sept. 16, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd.
TLSA
-0.90%
+ Free Alerts
("Tiziana" or the "Company"), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announces that it has been notified that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman has a beneficial interest, purchased 29,318 common shares priced between $0.78 and $0.81 per share.

The acquisition takes Mr Cerrone's interests from 37.70% to 37.72%.

david gruen
20/9/2022
11:01
Tiziana Life Sciences Announces Continued Clinical Improvements in the Second Patient with Secondary Progressive Multiple Sclerosis (SPMS) After Six Months of Dosing with Intranasal Foralumab
jpuff
09/9/2022
16:00
Chief medical officer buys more shares you have to have hope
michelle74
09/9/2022
14:24
What makes you think that?
david gruen
09/9/2022
14:22
Good news coming soon I think
michelle74
02/9/2022
11:11
lots and still worth diddly!
nerdofsteel
23/8/2022
10:38
depends, how many of these FREE shares you have!
abbynat
Chat Pages: 718  717  716  715  714  713  712  711  710  709  708  707  Older

Your Recent History

Delayed Upgrade Clock